Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses

Xu, Ke; Lu, Weinan; Yu, Airu; Wu, Hongwei; He, Jie

doi:10.1186/s12885-024-12130-y

Fig. 2

From: Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses

Comparison of PD-L1 expression, efficacy and prognosis between STK11^mut and STK11^wt patients with NSCLC. (A) Overall positive rate of PD-L1 expression. (B) Percentage of patients with PD-L1 expression ≥ 50%. (C) Percentage of patients with PD-L1 expression ≥ 1% and < 50%. (D) Rate of patients with KRAS mutation. (E) ORR of patients who received ICIs. (F) HR of progressive disease. (G) HR of death

Back to article page

Fig. 2

BMC Cancer

Contact us